In June 2026, the US Food and Drug Administration (FDA) approved the first oral carbapenem, tebipenem, for the treatment of complicated urinary tract infections (UTIs). While this approval paves the way for more convenient treatment without the need for hospitalisation, it also raises questions around stewardship and rates of carbapenem resistance.
Source link